ArticleJournal of gynecologic oncology2026
Treatment patterns and survival outcomes according to histologic subtype in malignant ovarian germ cell tumors: a nationwide real-world cohort study.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate real-world treatment patterns and survival outcomes by histologic subtype in patients with malignant ovarian germ cell tumors (MOGCTs) in Korea.
methodsUsing the Cancer Public Library Database, a retrospective cohort study was conducted including adult patients newly diagnosed with MOGCTs between 2013 and 2018. Patients were categorized into 3 histologic subtypes: dysgerminoma, non-dysgerminomatous germ cell tumors (ND-GCTs; yolk sac tumor, embryonal carcinoma, and mixed germ cell tumor [GCT]), and malignant teratomatous germ cell tumors (immature teratoma and teratocarcinoma). Initial treatment patterns, including surgery and chemotherapy, were examined. Overall survival (OS) was assessed by histologic subtype using the Kaplan-Meier method. In localized-stage patients, OS and time to first subsequent therapy or death (TFST) were estimated by adjuvant chemotherapy use, with subgroup analysis by histology.
resultsA total of 332 patients were included (27.7% dysgerminomas, 33.4% ND-GCTs, 38.9% malignant teratomatous GCTs). In localized disease, surgery alone was common in dysgerminomas (57.6%), while adjuvant chemotherapy was frequently used in ND-GCTs (88.5%) and malignant teratomatous GCTs (60.0%). Adjuvant chemotherapy was associated with longer TFST overall (p<0.01), but no OS benefit (p=0.22). In subgroup analysis, adjuvant chemotherapy was associated with longer TFST in ND-GCTs (p<0.01) and malignant teratomatous GCTs (p=0.04), but not in dysgerminomas. No significant differences in OS were observed in any group.
conclusionThis study highlights distinct treatment patterns and outcomes by histologic subtype in MOGCTs. These findings support the value of large population-based data in guiding treatment decisions for rare ovarian tumor subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.